To date, few clinical studies assessing PARP inhibitors in m(CR)PCa are available (Fong et al., 2009; Kaufman et al., 2015; Mateo et al., 2015; Sandhu et al., 2013). This evidence concerns the gene PARP1 and posterior cortical atrophy.